"With topline data expected for ELX-02 in Alport syndrome in the first half of 2023, we believe we are approaching a significant milestone for the company, to advance into our first Phase 3 study, with the potential to create significant value for both patients and shareholders," said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. "Positive data from the trial would also be a validation of our potential to treat other rare kidney diseases and develop small molecule genetic therapy products."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELOX:
- Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
- Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
- Eloxx submits IND to FDA for ZKN-013 for treatment of RDEB
- Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
- Eloxx Pharmaceuticals initiates ELX-02 trial